Health Condition 1: J840- Alveolar and parieto-alveolar conditions Health Condition 2: J128- Other viral pneumonia
Conditions
Interventions
Intervention1: Oral Clarithromycin 500 mg PO one tablet BiD for three months: Oral Clarithromycin 500 mg PO one tablet BiD for three months
Intervention2: Oral Clarithromycin 250 mg PO one tablet BiD
Sponsors
SELF DrIrfan Ismail Ayub
Eligibility
Inclusion criteria
Inclusion criteria: 1. All patients diagnosed with COVID 19 based on positive result on SARS-CoV2 RT-PCR or CBNAAT from nasopharyngeal or oropharyngeal swab or secretions. 2. More than two weeks, but less than six weeks have lapsed after the above diagnostic positive result. 3. A repeat nasopharyngeal or oropharyngeal swab test (either SARS-CoV2 RT-PCR or CBNAAT) performed at two weeks or later, after earlier positive result, is now negative. 4. CT scan of thorax performed after two weeks and less than six weeks after the first positive result, shows features of organizing pneumonia. Organizing pneumonia on CT scan of thorax is diagnosed when, one or more of the following features are identified on the CT scan images of thorax: 1.Unilateral or bilateral basal subpleural lobar, segmental or perilobular consolidation 2.Halo sign 3.Reverse halo sign or atoll sign 4.Target sign or bulls-eye sign or double halo sign
Exclusion criteria
Exclusion criteria: 1.Patient is unwilling to provide consent 2.Patients with preexisting parenchymal or interstitial lung disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients with complete resolution of lung findings at third month of follow up.Timepoint: Three months of follow up | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objective includes percentage of patients with more than 50% reduction in the CT severity score at three months, side effect and tolerance profile of patients in the Clarithromycin arm.Timepoint: Third month of follow up. However, every two weeks, a telephone consultation will be performed to assess side effects and symptom profile and drug compliance | — |
Countries
India
Contacts
Public ContactIrfan Ismail Ayub
Sri Ramachandra Institute of Higher Education and Research
Outcome results
None listed